Neutrophil-released enzymes can influence composition of circulating immune complexes in multiple sclerosis

References

• Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA. 2007;104:8433–8437.
   PubMed Web of Science ®Google Scholar
• Scanlan CN, Burton DR, Dwek RA. Making autoantibodies safe. Proc Natl Acad Sci USA. 2008;105:4081–4082.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–673.
   PubMed Web of Science ®Google Scholar
• Biermann MHC, Griffante G, Podolska MJ, et al. Sweet but dangerous - the role of immunoglobulin G glycosylation in autoimmunity and inflammation. Lupus. 2016;25:934–942.
   PubMed Web of Science ®Google Scholar
• Sjöwall C, Zapf J, von Löhneysen S, et al. Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. Lupus. 2015;24:569–581.
   PubMed Web of Science ®Google Scholar
• Fickentscher C, Magorivska I, Janko C, et al. The pathogenicity of anti-β2GP1-IgG autoantibodies depends on Fc glycosylation. J Immunol Res. 2015;2015:1–12.
   Google Scholar
• Magorivska I, Muñoz LEE, Janko C, et al. Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells. Clin Exp Immunol. 2016;184:110–117.
   PubMed Web of Science ®Google Scholar
• Seeling M, Brückner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?. Nat Rev Rheumatol. 2017;13:621–630.
   PubMed Web of Science ®Google Scholar
• Kao D, A, Lux A, Schaffert R, et al. IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. Eur J Immunol. 2017;47:2070–2079.
   PubMed Web of Science ®Google Scholar
• Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 2018;172:564–577.e13.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
   PubMed Web of Science ®Google Scholar
• Wuhrer M, Selman MHJ, McDonnell LA, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation. 2015;12:235.
   PubMed Web of Science ®Google Scholar
• Thaysen-Andersen M, Venkatakrishnan V, Loke I, et al. Human neutrophils secrete bioactive paucimannosidic proteins from azurophilic granules into pathogen-infected sputum. J Biol Chem. 2015;290:8789–8802.
   PubMed Web of Science ®Google Scholar
• Lucisano YM, Mantovani B. The role of complement in the stimulation of lysosomal enzyme release by polymorphonuclear leucocytes induced by immune complexes of IgG and of IgM. Immunology. 1988;65:171–175.
   PubMed Web of Science ®Google Scholar
• Schauer C, Janko C, Munoz LELE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20:511–517.
   PubMed Web of Science ®Google Scholar
• Shkandina T, Herrmann M, Bilyy R. Sweet kiss of dying cell: Sialidase activity on apoptotic cell is able to act toward its neighbors. Autoimmunity. 2012;45:574–578.
   PubMed Web of Science ®Google Scholar
• Muñoz LE, Herrmann M. When autologous chromatin becomes a foe. Autoimmunity. 2012;45:565–567.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36–49.
   PubMed Web of Science ®Google Scholar
• Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.
   PubMed Web of Science ®Google Scholar
• Owens T, Khorooshi R, Wlodarczyk A, Asgari N. Interferons in the central nervous system: A few instruments play many tunes. Glia. 2014;62:339–355.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Stümer J, Biermann MHCHC, Knopf J, et al. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. Clin Exp Immunol. 2017;189:372–382.
   PubMed Web of Science ®Google Scholar
• Tateno H, Winter HC, Goldstein IJ. Cloning, expression in Escherichia coli and characterization of the recombinant Neu5Acalpha2,6Galbeta1,4GlcNAc-specific high-affinity lectin and its mutants from the mushroom Polyporus squamosus. Biochem J. 2004;382:667–675.
   PubMed Web of Science ®Google Scholar
• Chen S, Lu C, Gu H, et al. Aleuria aurantia lectin (AAL)-reactive immunoglobulin G rapidly appears in sera of animals following antigen exposure. PLoS One. 2012;7:e44422.
   PubMed Web of Science ®Google Scholar
• Polman CH, Killestein J. Anti-myelin antibodies in multiple sclerosis: clinically useful?. J. Neurol Neurosurg Psychiatry. 2006;77:712.
   PubMedGoogle Scholar
• Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diag Ther. 2009;13:225–244.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Vojdani E, Cooper E. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, alpha-beta-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Intern Med. 2003;254:363–374.
   PubMed Web of Science ®Google Scholar
• Koriem KMM. Multiple sclerosis: New insights and trends. Asian Pac J Trop Biomed. 2016;6:429–440.
   Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Wiendl H, et al. Regulatory functions of natural killer cells in multiple sclerosis. Front Immunol. 2016;7:606.
   PubMed Web of Science ®Google Scholar
• Futamata E, Masuda S, Nishibata Y, et al. Vanishing immunoglobulins: the formation of pauci-immune lesions in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Nephron. 2018;138:328–330.
   PubMed Web of Science ®Google Scholar
• Li G, Jia J, Ji K, et al. The neutrophil elastase inhibitor, sivelestat, attenuates sepsis-related kidney injury in rats. Int J Mol Med. 2016;38:767–775.
   PubMed Web of Science ®Google Scholar
• Weyer AD, Stucky CL. Repurposing a leukocyte elastase inhibitor for neuropathic pain. Nat Med. 2015;21:429.
   PubMed Web of Science ®Google Scholar
• Vicuña L, Strochlic DE, Latremoliere A, et al. The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell–derived leukocyte elastase. Nat Med. 2015;21:518–523.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Aikawa N. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag. 2014;10:621–629.
   PubMed Web of Science ®Google Scholar